BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tezspire (tezepelumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tezspire (tezepelumab)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06705764-1507@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tezspire (tezepelumab): Phase 4 readout est. (NCT06705764)
DESCRIPTION:Tezspire (tezepelumab)\, phase 4\, Asthma.\nStudy: Tezepelumab 
 in the Treatment of Emergency Room Asthma in Adults (TERAA)\nEstimated pri
 mary completion: November 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tezepelumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06705764
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06189742-1507@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tezspire (tezepelumab): Phase 2 readout est. (NCT06189742)
DESCRIPTION:Tezspire (tezepelumab)\, phase 2\, Asthma.\nStudy: Tezepelumab 
 in Allergic Rhinitis and Asthma Study (TEZARS)\nEstimated primary completi
 on: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/te
 zepelumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06189742
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06706817-1507@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20270113
DTEND;VALUE=DATE:20270114
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT06706817)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3.\nStudy: A Study to Investigat
 e Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis Wi
 th Nasal Polyposis Initiating Treatment With Tezepelumab\nEstimated primar
 y completion: 13 January 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/tezepelumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06706817
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06473779-1507@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20270625
DTEND;VALUE=DATE:20270626
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT06473779)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3\, Asthma.\nStudy: Open-label S
 tudy to Assess Reduction of Background Asthma Medication While Sustaining 
 Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yr
 s With Severe Asthma.\nEstimated primary completion: 25 June 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/tezepelumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06473779
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07757841-1507@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tezspire (tezepelumab): Phase na readout est. (NCT07757841)
DESCRIPTION:Tezspire (tezepelumab)\, phase na\, Asthma.\nStudy: Real-World 
 Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis\nE
 stimated primary completion: 30 June 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/tezepelumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07757841
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07046117-1507@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tezspire (tezepelumab): Phase na readout est. (NCT07046117)
DESCRIPTION:Tezspire (tezepelumab)\, phase na\, Asthma.\nStudy: Effect of T
 ezepelumab on Barrier Function in Severe Asthmatic Patients With and Witho
 ut Comorbid Chronic Rhinosinusitis With Nasal Polyps\nEstimated primary co
 mpletion: 31 January 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/tezepelumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07046117
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07363642-1507@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20280207
DTEND;VALUE=DATE:20280208
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT07363642)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3\, Asthma.\nStudy: Phase 3b Stu
 dy in Patients With Severe Asthma Treated With Tezepelumab\nEstimated prim
 ary completion: 7 February 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/tezepelumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07363642
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07520162-1507@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT07520162)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3.\nStudy: A Study to Investigat
 e NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Tr
 eatment With Tezepelumab\nEstimated primary completion: 1 March 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tezepelumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07520162
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06023589-1507@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT06023589)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3\, Asthma.\nStudy: A Study to I
 nvestigate the Efficacy and Safety of Tezepelumab Compared With Placebo in
  Children 5 to < 12 Years Old With Severe Asthma\nEstimated primary comple
 tion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/te
 zepelumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06023589
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07771855-1507@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Tezspire (tezepelumab): Phase 2 readout est. (NCT07771855)
DESCRIPTION:Tezspire (tezepelumab)\, phase 2.\nStudy: Efficacy of an Anti-T
 SLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Ind
 uced by Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Stem
  Cells Transplantation Recipients\nEstimated primary completion: January 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tezepelumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07771855
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06883305-1507@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20290313
DTEND;VALUE=DATE:20290314
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT06883305)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3\, Chronic Obstructive Pulmonar
 y Disease.\nStudy: A Study to Investigate the Efficacy and Safety of Tezep
 elumab in Adult Participants With Moderate to Very Severe COPD (D5241C0000
 6)\nEstimated primary completion: 13 March 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tezepelumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06883305
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06878261-1507@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20290313
DTEND;VALUE=DATE:20290314
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT06878261)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3\, Chronic Obstructive Pulmonar
 y Disease.\nStudy: A Study to Investigate the Efficacy and Safety of Tezep
 elumab in Adult Participants With Moderate to Very Severe COPD (D5241C0000
 7)\nEstimated primary completion: 13 March 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tezepelumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06878261
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07015996-1507@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Tezspire (tezepelumab): Phase 2 readout est. (NCT07015996)
DESCRIPTION:Tezspire (tezepelumab)\, phase 2.\nStudy: Efficacy of Tezepelum
 ab in Peanut Oral Immunotherapy\nEstimated primary completion: May 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tezepelumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07015996
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07013123-1507@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20290818
DTEND;VALUE=DATE:20290819
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT07013123)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3\, Asthma.\nStudy: Potency of H
 DM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in
  HDM Allergic Patients With Severe Asthma\, Treated With Tezepelumab\nEsti
 mated primary completion: 18 August 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tezepelumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07013123
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
